Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.

Saved in:
Bibliographic Details
Title: Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.
Authors: Major A; The University of Chicago Comprehensive Cancer Center, Chicago, IL.; University of Colorado Cancer Center, Aurora, CO., Yu J; The University of Chicago Comprehensive Cancer Center, Chicago, IL., Shukla N; The University of Chicago Comprehensive Cancer Center, Chicago, IL., Che Y; The University of Chicago Comprehensive Cancer Center, Chicago, IL., Karrison TG; The University of Chicago Comprehensive Cancer Center, Chicago, IL., Treitman R; University of Colorado Cancer Center, Aurora, CO., Kamdar MK; University of Colorado Cancer Center, Aurora, CO., Haverkos BM; University of Colorado Cancer Center, Aurora, CO., Godfrey J; City of Hope Comprehensive Cancer Center, Duarte, CA., Babcook MA; The Ohio State University James Comprehensive Cancer Center, Columbus, OH., Voorhees TJ; The Ohio State University James Comprehensive Cancer Center, Columbus, OH., Carlson S; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA., Gaut D; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA., Oliai C; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA., Romancik JT; Winship Cancer Institute at Emory University, Atlanta, GA., Winter AM; Taussig Cancer Institute at Cleveland Clinic, Cleveland, OH., Hill BT; Taussig Cancer Institute at Cleveland Clinic, Cleveland, OH., Bansal R; Mayo Clinic Rochester, Rochester, MN., Villasboas Bisneto JC; Mayo Clinic Rochester, Rochester, MN., Nizamuddin IA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL., Karmali R; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL., Fitzgerald LA; Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT., Stephens DM; Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT., Pophali PA; University of Wisconsin Carbone Cancer Center, Madison, WI., Trabolsi A; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL., Schatz JH; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL., Hu M; Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Bachanova V; Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Slade MJ; Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO., Singh N; Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO., Ahmed N; The University of Kansas Cancer Center, Kansas City, KS., McGuirk JP; The University of Kansas Cancer Center, Kansas City, KS., Bishop MR; The University of Chicago Comprehensive Cancer Center, Chicago, IL.; David and Etta Jonas Center for Cellular Therapy, The University of Chicago Medicine, Chicago, IL., Riedell PA; The University of Chicago Comprehensive Cancer Center, Chicago, IL.; David and Etta Jonas Center for Cellular Therapy, The University of Chicago Medicine, Chicago, IL., Kline J; The University of Chicago Comprehensive Cancer Center, Chicago, IL.; David and Etta Jonas Center for Cellular Therapy, The University of Chicago Medicine, Chicago, IL.
Source: Blood advances [Blood Adv] 2023 Aug 22; Vol. 7 (16), pp. 4528-4538.
Publication Type: Journal Article; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2023010016